AI Enablement for Life Sciences & Pharma

Life sciences has the model risk discipline, the regulatory frame, and the molecular-data abundance to be AI-native — and the operating model has not yet caught up

Life sciences is structurally one of the most interesting AI enablement opportunities anywhere. The R&D function generates data at machine scale. The clinical function runs structured workflows with explicit endpoint definitions. Manufacturing and supply run on validated processes with continuous quality data. The regulatory function has decades of experience with model-driven submissions. Model risk discipline already exists in clinical biostatistics and CMC analytics.

And yet, of the pharma, biotech, and medical device companies we work with, almost all of them describe the same picture: an AI strategy concentrated in early discovery (where the science is exciting and the regulatory exposure is low), bolt-on AI in clinical operations and pharmacovigilance, and an operating model in commercial, manufacturing, and regulatory affairs that has barely changed in a decade. R&D productivity that has not kept pace with investment. Time-to-market that competitors with AI-native operating models are quietly compressing.

The structural opportunity is to rebuild clinical operations, pharmacovigilance, regulatory affairs, and manufacturing & supply around AI as a native capability — under the GxP, ICH, and EU AI Act frameworks the industry runs on. The companies that solve this first will operate at structurally lower cost-to-trial, faster time-to-submission, and faster time-to-market than competitors who do not.

Is this you?

• Your AI strategy is concentrated in discovery and you have very little structural AI capability in clinical, regulatory, manufacturing, or commercial.
• Your clinical operations still depend on manual data review, manual query management, and a CRO ecosystem that produces variable data quality.
• Your regulatory affairs function spends material time on document assembly, cross-reference checking, and submission formatting that could be automated under proper validation.
• Your pharmacovigilance operation scales linearly with case volume and post-marketing safety reporting is a continuous firefight.
• Your manufacturing and CMC analytics sit in a Validated Computer System under GxP and you cannot see how to introduce ML without a multi-year compliance programme.
• Your supply chain and demand planning is still built around quarterly forecasts and quarterly S&OP cycles in a market where competitors are running real-time.
• Your AI portfolio has 30+ initiatives and you couldn't honestly tell the executive committee which ones are compounding.

If three or more of these are true, you are in the right conversation.

Where we focus in life sciences

Five priority value streams account for almost all of the structural opportunity in a typical pharmaceutical, biotech, or medical device company. We sequence the work based on which one has the highest combined cost, regulatory, and time-to-market impact for your specific situation.

1. Clinical operations and trial execution

The single largest cost line in most pharma R&D and the value stream where AI enablement has the highest commercial leverage. Site selection, patient recruitment, monitoring, query management, data cleaning, lock — most clinical operations runs on a combination of vendor EDC, CTMS, and IRT platforms with significant manual data review and CRO hand-offs. The redesigned version handles routine data review, query generation, and monitoring triage end-to-end with full audit trails, concentrates monitor and biostatistician attention on the genuinely ambiguous cases, and turns those decisions back into structured training signal. Cost-per-trial drops, time-to-database-lock compresses, and the data quality posture under inspection improves.

Regulatory frame: ICH E6 (R3), GCP, FDA 21 CFR Part 11 (US), MHRA (UK), EMA (EU), ICH E9 statistical principles, EU AI Act for any clinical decision support models.

2. Pharmacovigilance and safety operations

The post-marketing safety operation where case volumes have grown faster than headcount and where the bar for case processing speed and quality keeps rising. Most PV operations run on a combination of vendor case management platforms (Argus, ARISg) with manual case intake, narrative drafting, MedDRA coding, and signal detection. The redesigned version handles routine ICSR intake, narrative drafting, MedDRA coding, and signal triage end-to-end, concentrates case officer and signal analyst attention on the cases that matter, and turns expert decisions back into structured training signal.

Regulatory frame: FDA 21 CFR 314.80 / 600.80 / 803, EMA Module VI on PV, ICH E2D / E2E, GVP (Good Pharmacovigilance Practices), MHRA, the Yellow Card scheme and equivalent national systems.

3. Regulatory affairs and submission operations

Regulatory affairs is one of the most document-heavy value streams in life sciences and one of the most amenable to AI enablement. NDA / BLA / MAA assembly, change control, labelling updates, health authority correspondence, the eCTD lifecycle. Most pharma RA functions run on a combination of vendor RIM platforms (Veeva, ArisGlobal) with substantial manual document handling. The redesigned version handles routine document assembly, cross-reference checking, change impact analysis, and submission packaging end-to-end, concentrates regulatory professional attention on strategy and health authority dialogue, and compresses cycle time on the operational side of regulatory affairs.

Regulatory frame: FDA, MHRA, EMA, Health Canada, PMDA, ICH M1 / M4 / M8 / E2B, eCTD specifications, the relevant national health authority guidelines.

4. Manufacturing, supply chain, and CMC

Pharma manufacturing runs under GxP and the validation bar is high. Most companies have not yet figured out how to deploy ML inside a Validated Computer System without a multi-year compliance programme. The redesigned version treats validation as a first-class engineering constraint rather than a barrier — and uses the relatively new ICH Q9(R1) Quality Risk Management framework and the FDA's CSA (Computer Software Assurance) approach to deploy ML responsibly inside the validated environment. The S&OP and supply chain layer above CMC also gets the action-data treatment.

Regulatory frame: FDA 21 CFR Parts 210/211 (US cGMP), EU GMP Annex 1 (sterile), Annex 11 (computerised systems), Annex 15 (validation), ICH Q7 / Q8 / Q9(R1) / Q10 / Q12, FDA CSA, EU AI Act for any quality-affecting AI systems.

5. Commercial and medical affairs

The commercial value stream that historically has been hard to systematise. KOL identification and engagement, medical information requests, scientific dialogue with the field, real-world evidence generation, payer-facing economic analysis. Most commercial functions run this through manual CRM and content management with substantial human time. The redesigned version handles routine KOL signal capture, MI request triage, and content compliance review end-to-end, concentrates field medical and commercial attention on the high-value scientific conversations.

Regulatory frame: FDA OPDP (US), MHRA Blue Guide (UK), EFPIA / IFPMA codes, ABPI Code (UK), promotional compliance frameworks, Sunshine Act and equivalent transparency rules.

What we actually do in a life sciences engagement

Our work spans the same five enablement pillars as our flagship AI Enablement service, tailored to life sciences realities:

• Production function redesign — workflow rebuilds in BPMN 2.0, anchored to one priority value stream and sequenced from there, with explicit consideration of the validation lifecycle
• Action-data layer architecture — built around study and patient wide-rows, ICSR event streams, eCTD content stores, and CMC quality data, with observable lineage from source systems through to the model
• Decision systems and feedback loops — structured override capture from clinical, regulatory, and PV professionals, decision logs queryable for any individual case, continuous retraining within validation constraints
• Operating model and roles — first-line accountability, GxP integration, system supervisor roles for the operations functions, exception handler career paths
• Embedded governance — three-lines-of-defence integrated with the existing GxP, GVP, and quality functions, evidence as a by-product of build, regulatory dialogue with FDA / MHRA / EMA built into the cadence

The difference in life sciences is the validation lifecycle and the GxP discipline. Any AI deployment in a GxP environment has to satisfy the validation expectations of FDA CSA, EU GMP Annex 11, and the relevant ICH guidance. We treat validation as an engineering constraint that shapes the design, not a downstream check.

How a typical life sciences engagement runs

Phase 1 — Diagnostic (Weeks 1–6)

We map your existing AI portfolio across discovery, clinical, regulatory, PV, and manufacturing, triage your use cases against ICH, GxP, and EU AI Act expectations, run an honest current-state mapping of one priority workflow, and produce a defensibility memo against your highest-risk in-production models.

Outputs: AI portfolio audit, regulatory and validation triage, current-state map of priority workflow, defensibility memo, board-ready strategic narrative.

Phase 2 — Strategy & Blueprint (Weeks 7–14)

We design the future-state operating model for your priority value stream, including the action-data layer architecture, decision rights matrix, validation strategy, governance machinery, and the operating model implications.

Outputs: Operating model blueprint, redesigned workflow specification, data architecture, decision rights matrix, validation and governance framework, sequenced implementation roadmap.

Phase 3 — Activation & Delivery (Months 4–24)

We embed alongside your operations, technology, regulatory, quality, and risk teams to lead the rebuild. Data layer first, then workflow, then validation and governance instrumentation, then the role design changes.

Outputs: Live redesigned workflow with measurable outcomes, action-data platform reusable across adjacent workflows, validated AI components, embedded governance machinery, named first-line owners, retrained operational professionals.

Engagement models

Every life sciences engagement is scoped to your specific operating model, priority value stream, regulatory environment (FDA, MHRA, EMA, ICH), and the validation lifecycle. We commit to pricing transparently once we understand your situation.

Life Sciences Diagnostic (~6 weeks) — A focused diagnostic on one priority value stream. Portfolio audit, regulatory and validation triage, current-state mapping, board-ready strategic narrative.

Life Sciences Strategy & Blueprint (~12–14 weeks) — The full Phase 1 + Phase 2 engagement. Operating model blueprint, redesigned priority workflow, data architecture, validation and governance framework, sequenced 18-month roadmap.

Life Sciences Transformation Programme (12–24 months) — Strategy plus hands-on delivery. Senior practitioners embedded alongside your teams, leading the workflow rebuilds, overseeing data layer implementation, and running the change programme.

Executive Advisory Retainer (ongoing) — Senior advisory access for life sciences companies already executing on an enablement strategy.

For a detailed breakdown of each shape, see our engagements page.

Why this work is different in life sciences

A few honest observations:

Validation is a first-class engineering constraint, not a barrier. GxP validation is real and the bar is high — but it is not an excuse to avoid AI enablement work. The FDA's CSA approach and ICH Q9(R1) Quality Risk Management give the industry a defensible framework for responsible ML deployment inside the validated environment. We engage validation specialists from day one and design the workflow to satisfy validation expectations as a by-product of build.

Discovery is the easy part. The operational backbone is where the structural value is. Most life sciences AI strategy is concentrated in discovery (target identification, hit selection, lead optimisation). The science is exciting and the regulatory exposure is low, so the work is comparatively easy to defend. The hard work — and the bigger commercial leverage — is in clinical, regulatory, PV, and manufacturing.

The CRO and vendor landscape is dense. Most pharma R&D operates through a complex CRO ecosystem and an EDC / CTMS / IRT vendor landscape. The redesign work has to engage that landscape rather than pretending it can be replaced.

Quality and regulatory professionals are your most natural internal partners. Quality, validation, and regulatory affairs professionals already think in terms of risk-based approaches, evidence, and audit trail. They are usually the best collaborators on AI enablement work — once they see that the engagement respects the validation discipline.

Time-to-market is the binding commercial metric. The companies that compress regulatory submission cycles, clinical trial execution, and CMC change control will win on time-to-market. AI enablement in the operational backbone is one of the few credible levers on that metric.

Who this is for

We work best with pharmaceutical, biotech, and medical device companies that meet at least three of the following:

• Mid-cap or large-cap scale — substantial commercial portfolio, multiple molecules in clinical development, or systemically important medical device manufacturer
• Executive sponsor at COO, CMO, CRO (chief regulatory), Head of R&D, or Chief Quality Officer level
• A real (not theoretical) AI ambition in the operational backbone, not just discovery
• Regulatory exposure to FDA, MHRA, EMA, ICH, GxP that makes governance non-negotiable
• Some existing AI portfolio to triage — usually concentrated in discovery and bolt-on clinical or PV tools

Frequently asked questions

How is this different from your flagship AI Enablement service?

The flagship AI Enablement service is sector-agnostic. This is the same five-pillar engagement structure with a life sciences lens: the value streams (clinical operations, PV, regulatory affairs, manufacturing, commercial), the regulatory frame (FDA, MHRA, EMA, ICH, GxP, EU AI Act), and the sector-specific failure modes (validation barriers, vendor density, CRO complexity).

Do you work in discovery as well as the operational backbone?

We can — but the operational backbone (clinical, regulatory, PV, manufacturing, commercial) is where most of the structural value is. Most pharma already has reasonable AI capability in discovery; very few have it in the operational backbone. We bias toward the under-served value streams.

How do you handle GxP validation?

As an engineering constraint, not a downstream check. We engage validation specialists from day one and design the workflow to satisfy GxP, FDA CSA, and EU GMP Annex 11 expectations as a by-product of build. ICH Q9(R1) gives us the risk-based foundation.

Do you work with med device companies as well as pharma?

Yes. The regulatory frame differs (EU MDR / IVDR, FDA SaMD guidance) but the structural framework is the same. We tailor the engagement to your product type.

How does this fit with our existing CRO relationships?

We engage CROs as part of the value stream rather than working around them. In several engagements, the CRO has become a productive partner in the redesign work — particularly where clinical data quality is the binding constraint.

What this looks like in practice

A note on case studies. Our published case studies are currently concentrated in financial services, where we have the longest public track record. Life sciences engagements are subject to confidentiality agreements with pharmaceutical and biotech sponsors that do not yet permit publication. The structural pattern (data layer rebuild, workflow redesign, embedded GxP-aligned governance) is the same as in the financial services cases — the regulatory frame, the validation discipline, and the value streams are what differ. We are happy to walk you through the relevant life sciences work under NDA in the diagnostic working session.

Start here

The first step is an executive working session — 90 minutes, no deck, no pitch. We use the time to understand your current operating model, your AI portfolio, the regulatory environment you operate in, and the value streams where the structural opportunity is largest. If we are a fit, we scope the diagnostic. If we are not, we say so.

For supporting depth, see the pillar essay on what AI enablement actually means and the AI Enablement Maturity Diagnostic.